发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
发布时间
2026/03/25 04:5812 分钟前源站更新
2026/03/25 04:5812 分钟前首次抓取
2026/03/25 04:5812 分钟前发布时间
12 分钟前源站更新
12 分钟前首次抓取
12 分钟前用于追踪这条内容的来源与记录标识。
Source
原始链接
‘Too Big to Ban’ Chinese Firm Gains 100% on GLP-1 Chokehold Investors are still piling into the stock betting the firm will remain central to the global supply of obesity, cancer and other drugs.
发布时间
54 天前
2026-08-16 23:00:00 UTC
源站更新
53 天前
2026-08-17 02:04:45 UTC
首次抓取
54 天前
2026-08-16 23:28:48 UTC
尽管被美国国防部列为中国军方关联企业，药明康德股价仍创历史新高，较 1 月翻倍，得益于 GLP-1 药物制造主导地位和上半年业绩超预期。投资者押注其“大到不能禁”，美国业务收入占比持续上升。
Despite the Pentagon's military-linked designation, WuXi AppTec shares hit a record high and doubled from January, fueled by its dominant role in GLP-1 drug manufacturing and strong H1 results. Investors bet the firm is 'too big to ban,' with US revenue share still rising.
用于追踪这条内容的来源与记录标识。
